Analysis of the mechanism of polycythemia vera by studying JAK2 mutant-induced signaling pathway

Research output: Contribution to journalArticle

Abstract

It has been well established that disruption of JAK2 signaling regulation is involved in various hematopoietic disorders; however, the detailed mechanism by which abnormal activation of JAK2 exhibits transforming activity remains to be elucidated. The somatic JAK2 mutation (V617F) was identified in most patients withpolycythemia vera (PV). Here, we show that JAK2 V617F mutant was constitutively active and exhibited tumorigenesis activity as a potent oncogene when erythropoietin receptor (EpoR) was co-expressed. To clarify the signaling pathway of JAK2 V617F mutant, we investigated the functional role of downstream transcription factor STAT5 in its induced cellular transformation and tumorigenesis in nude mice. Interestingly, JAK2 V617F mutant failed to exhibit transforming activity when STAT5 activation was inhibited utilizing EpoR mutant (HM). Furthermore, the expression of constitutively active STAT5 mutant (1*6) exhibited transforming activity. Taking these observations together, it is concluded STAT5 plays an essential role in EpoR-JAK2 V617F mutant-induced hematopoietic disorder and would be a good target for the treatment of PV.

Original languageEnglish
Pages (from-to)1183-1187
Number of pages5
JournalYakugaku Zasshi
Volume131
Issue number8
DOIs
Publication statusPublished - 2011

Fingerprint

Erythropoietin Receptors
Polycythemia Vera
Carcinogenesis
STAT5 Transcription Factor
Oncogenes
Nude Mice
Mutation
Therapeutics

Keywords

  • Janus kinase 2 (JAK2)
  • Polycythemia vera
  • STAT5
  • V617F mutation

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Analysis of the mechanism of polycythemia vera by studying JAK2 mutant-induced signaling pathway. / Tago, Megumi.

In: Yakugaku Zasshi, Vol. 131, No. 8, 2011, p. 1183-1187.

Research output: Contribution to journalArticle

@article{3e59d46ab2f0488abc1156accc41e54b,
title = "Analysis of the mechanism of polycythemia vera by studying JAK2 mutant-induced signaling pathway",
abstract = "It has been well established that disruption of JAK2 signaling regulation is involved in various hematopoietic disorders; however, the detailed mechanism by which abnormal activation of JAK2 exhibits transforming activity remains to be elucidated. The somatic JAK2 mutation (V617F) was identified in most patients withpolycythemia vera (PV). Here, we show that JAK2 V617F mutant was constitutively active and exhibited tumorigenesis activity as a potent oncogene when erythropoietin receptor (EpoR) was co-expressed. To clarify the signaling pathway of JAK2 V617F mutant, we investigated the functional role of downstream transcription factor STAT5 in its induced cellular transformation and tumorigenesis in nude mice. Interestingly, JAK2 V617F mutant failed to exhibit transforming activity when STAT5 activation was inhibited utilizing EpoR mutant (HM). Furthermore, the expression of constitutively active STAT5 mutant (1*6) exhibited transforming activity. Taking these observations together, it is concluded STAT5 plays an essential role in EpoR-JAK2 V617F mutant-induced hematopoietic disorder and would be a good target for the treatment of PV.",
keywords = "Janus kinase 2 (JAK2), Polycythemia vera, STAT5, V617F mutation",
author = "Megumi Tago",
year = "2011",
doi = "10.1248/yakushi.131.1183",
language = "English",
volume = "131",
pages = "1183--1187",
journal = "Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "8",

}

TY - JOUR

T1 - Analysis of the mechanism of polycythemia vera by studying JAK2 mutant-induced signaling pathway

AU - Tago, Megumi

PY - 2011

Y1 - 2011

N2 - It has been well established that disruption of JAK2 signaling regulation is involved in various hematopoietic disorders; however, the detailed mechanism by which abnormal activation of JAK2 exhibits transforming activity remains to be elucidated. The somatic JAK2 mutation (V617F) was identified in most patients withpolycythemia vera (PV). Here, we show that JAK2 V617F mutant was constitutively active and exhibited tumorigenesis activity as a potent oncogene when erythropoietin receptor (EpoR) was co-expressed. To clarify the signaling pathway of JAK2 V617F mutant, we investigated the functional role of downstream transcription factor STAT5 in its induced cellular transformation and tumorigenesis in nude mice. Interestingly, JAK2 V617F mutant failed to exhibit transforming activity when STAT5 activation was inhibited utilizing EpoR mutant (HM). Furthermore, the expression of constitutively active STAT5 mutant (1*6) exhibited transforming activity. Taking these observations together, it is concluded STAT5 plays an essential role in EpoR-JAK2 V617F mutant-induced hematopoietic disorder and would be a good target for the treatment of PV.

AB - It has been well established that disruption of JAK2 signaling regulation is involved in various hematopoietic disorders; however, the detailed mechanism by which abnormal activation of JAK2 exhibits transforming activity remains to be elucidated. The somatic JAK2 mutation (V617F) was identified in most patients withpolycythemia vera (PV). Here, we show that JAK2 V617F mutant was constitutively active and exhibited tumorigenesis activity as a potent oncogene when erythropoietin receptor (EpoR) was co-expressed. To clarify the signaling pathway of JAK2 V617F mutant, we investigated the functional role of downstream transcription factor STAT5 in its induced cellular transformation and tumorigenesis in nude mice. Interestingly, JAK2 V617F mutant failed to exhibit transforming activity when STAT5 activation was inhibited utilizing EpoR mutant (HM). Furthermore, the expression of constitutively active STAT5 mutant (1*6) exhibited transforming activity. Taking these observations together, it is concluded STAT5 plays an essential role in EpoR-JAK2 V617F mutant-induced hematopoietic disorder and would be a good target for the treatment of PV.

KW - Janus kinase 2 (JAK2)

KW - Polycythemia vera

KW - STAT5

KW - V617F mutation

UR - http://www.scopus.com/inward/record.url?scp=79961038712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961038712&partnerID=8YFLogxK

U2 - 10.1248/yakushi.131.1183

DO - 10.1248/yakushi.131.1183

M3 - Article

C2 - 21804321

AN - SCOPUS:79961038712

VL - 131

SP - 1183

EP - 1187

JO - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

JF - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

SN - 0031-6903

IS - 8

ER -